The Hospital Formulary: Introduction 101
SKS Medication Safety Series, Chapter 2 of 15 · Standard SİY02
Prof. Dr. Mehmet Nurullah Kurutkan, Düzce Üniversitesi İşletme Fakültesi Sağlık Yönetimi Bölümü
Chapter at a glance
A hospital formulary is the hospital’s own list of approved medicines, together with the information prescribers need to use them. This chapter explains what a formulary is, how committees build and review it, how it connects to electronic prescribing and rational use, and why the research base is thin. It corresponds to SKS standard SİY02, which also lists the minimum content of the formulary (Sağlık Bakanlığı, 2020).
Evidence base: 95 records of a 4948-record Web of Science corpus on hospital medication safety (Section 7). Reading time: about 25 minutes. Prior knowledge required: none.
Learning objectives
After working through this chapter, the reader should be able to:
- define a hospital formulary and list the minimum content required by SKS SİY02;
- describe how pharmacy and therapeutics committees manage formulary decisions;
- explain how formulary restrictions are enforced through information systems;
- evaluate the limits of the current evidence on formularies and safety.
Key concepts
- Hospital formulary (Hastane formülerleri): the approved list of medicines with essential prescribing information
- Non-formulary medication: a drug used in the hospital without being on the approved list
- Formulary restriction: a rule limiting who may prescribe a drug or for which indication
- Essential medicines list: a national or WHO list that can anchor a hospital formulary
- Pharmacy and therapeutics (P&T) committee: the body that adds, removes and reviews formulary items
Contents: How this chapter was produced · 1. Introduction · 2. History and development · 3. Definitions and conceptual schema · 4. Distinguishing it from neighbouring concepts · 5. Types and classifications · 6. Theoretical frameworks and models · 7. Themes and bibliometric profile · 8. The situation in Türkiye · 9. Debates and contradictions in the literature · 10. Measurement problems · 11. Research gaps and agenda · 12. Implications for practice today · Summary · Discussion questions · Further reading · Glossary · References · Source verification and AI use statement · Data and supplementary material
How this chapter was produced
Box 1. Method
Database: Web of Science Core Collection (SCI-EXPANDED, SSCI, ESCI); English; articles and reviews (including early access). Search date: 16 November 2026; all years (1981 to 2027).
Search: (#1 medication safety and error terms AND #2 hospital settings AND #3 fifteen SKS content blocks) NOT #4 animal and preclinical terms; the full string is on the series hub.
Screening: five export files (4955 records) were merged; 7 duplicates were removed by WoS accession number, DOI and normalised title plus year, leaving 4948 records. Records were assigned to this sub-topic when its term set (formulary, formularies) appeared in the title or keywords or, for this thin sub-topic, the abstract; a record can belong to several sub-topics. Included here: 95 records (5 with the term in the title; 10 reviews).
Limitations: single database; English only; assignment by term matching, checked by reading titles of the most cited and most recent records; claims are checked against abstracts, not full texts.
4955 records
5 title matches; 10 reviews
other chapters or general records
1. Introduction
When a junior physician needs to calculate a paediatric dose at night, or a nurse needs to know whether two infusions can share a line, the first reference should be the hospital formulary. SKS defines the formulary as a reference source for doctors and pharmacists containing the most effective, safe and economical medicines for the hospital’s health problems and the basic drug information needed for prescribing (Sağlık Bakanlığı, 2020). At a minimum it must include summary pharmacological and therapeutic information for rational use; pharmacy working hours and out-of-hours procedures; treatment-related information such as paediatric dose calculation, emergency dose tables, abbreviations, clinically important interactions and first-line treatment of poisoning; and rules for disposing of waste and expired medicines (Sağlık Bakanlığı, 2020).
The formulary is therefore both a selection tool (which medicines are available) and a knowledge tool (how they are used safely). Most of the international literature examines the first role.
2. History and development
The earliest record touching the formulary links military pharmacy automation with pharmacoepidemiology (Grabenstein et al., 1992). Through the 2000s formularies appeared mainly as context: a review of inappropriate prescribing in hospitalised older adults named formulary limitations among the barriers to good prescribing (Page et al., 2010). From 2017 onward, studies address formulary management directly, including annual review of non-formulary approvals (Her et al., 2017), national essential medicines policy at hospital level (Saravdekar et al., 2019), pharmacogenomics in committee decisions (Brown et al., 2025), compliance with national formulary restrictions (Latifah et al., 2026) and specialty subcommittees in multihospital systems (Treu et al., 2026).
- 1992 Pharmacoepidemiology and military medical automation (Grabenstein et al., 1992).
- 2010 Formulary limits named as a barrier to appropriate prescribing in older inpatients (Page et al., 2010).
- 2017 Review of non-formulary medication approvals in an academic centre (Her et al., 2017); national survey of P&T committees (Matlala et al., 2017).
- 2019 Hospital formulary built on the national essential medicines list in India (Saravdekar et al., 2019).
- 2025 Pharmacogenomics enters formulary management (Brown et al., 2025).
- 2026 Emergency medicine formulary subcommittee in a health system (Treu et al., 2026); national formulary compliance in Indonesia (Latifah et al., 2026).
3. Definitions and conceptual schema
| Source | Year | Discipline | Definition (paraphrased) | Emphasised dimension |
|---|---|---|---|---|
| Sağlık Bakanlığı, 2020 | 2020 | Accreditation standard | Reference source listing the most effective, safe and economical medicines with the basic information needed to prescribe them. | Knowledge and selection |
| Saravdekar et al., 2019 | 2019 | Health policy | A hospital formulary policy aligned with the national list of essential medicines to secure therapeutic and financial benefit. | Access and cost |
| Her et al., 2017 | 2017 | Hospital pharmacy | A list subject to formal annual review, with non-formulary use tracked as a signal for review. | Review and control |
| Latifah et al., 2026 | 2026 | Health insurance | National formulary restrictions, including prescriber authorisation criteria, that control cost and promote rational use. | Restriction and compliance |
| Brown et al., 2025 | 2025 | Clinical pharmacology | A formulary system that can integrate genotype information into selection and restriction. | Precision prescribing |
an approved, regularly reviewed list of medicines that steers prescribing towards effective, safe and affordable choices
All definitions share the idea of steering prescribing. SKS stresses the knowledge content of the document (Sağlık Bakanlığı, 2020), whereas the international literature stresses selection, cost and compliance (Latifah et al., 2026; Saravdekar et al., 2019).
4. Distinguishing it from neighbouring concepts
The formulary overlaps with governance, because the committee that owns it is a governance body, and with rational use and prescribing, because restrictions act at the moment of ordering (Figure 4). In this corpus most records mention the formulary in the abstract rather than the title, which is itself a finding: formulary management is rarely studied as a safety intervention.
| Neighbouring concept | How it differs |
|---|---|
| Governance (SİY01) | The committee or team is the owner; the formulary is one of its products (Matlala et al., 2017). |
| Rational use and stewardship (SİY01.02) | Stewardship changes how listed drugs are used; the formulary decides which drugs are listed (Latifah et al., 2026). |
| Clinical decision support | Software that can enforce formulary rules; alerts are often overridden (Nanji et al., 2018). |
| Essential medicines list | A national list; the hospital formulary adapts it to local needs (Saravdekar et al., 2019). |
5. Types and classifications
The records suggest three kinds of formulary: closed formularies with formal approval for non-listed drugs (Her et al., 2017); formularies anchored on a national list of essential or reimbursed medicines (Latifah et al., 2026; Saravdekar et al., 2019); and specialty or subcommittee formularies that manage a defined patient population within a larger system (Treu et al., 2026).
6. Theoretical frameworks and models
No explicit theory of the formulary appears in the corpus. Studies implicitly use a health technology assessment logic (effectiveness, safety, cost) (Saravdekar et al., 2019) and a compliance logic in which information systems enforce rules (Latifah et al., 2026). Precision medicine adds a new criterion, the expected response by genotype (Brown et al., 2025).
7. Themes and bibliometric profile
Only five records name the formulary in their title, so the sub-topic is the thinnest of the series together with returns and waste. Most of the 95 records mention formularies while studying something else, such as decision support or inappropriate prescribing (Nanji et al., 2018; Scott et al., 2018). Figure 5 shows the profile.
Records per year 2026 (incomplete)
Most frequent journals
Most frequent countries
Most frequent author keywords: patient safety (9), medication safety (8), medication errors (8), formularies (8), pharmacy, institutional, hospital (7), prescribing (7), data collection (6), hospitals (6), pharmacy and therapeutics committee (6), pharmaceutical services (6).
8. The situation in Türkiye
No formulary record in the corpus has a Turkish address. In Türkiye the content of the hospital formulary is prescribed by SKS SİY02 (Sağlık Bakanlığı, 2020); its use and effects have not been evaluated in the indexed literature captured here.
9. Debates and contradictions in the literature
Cost control or safety? Formulary policy is justified both by economics and by quality (Saravdekar et al., 2019). When restrictions are mainly financial, prescribers may perceive them as barriers to good care, as noted for older inpatients (Page et al., 2010).
Strict enforcement or flexibility? Information-system enforcement improves compliance with national restrictions (Latifah et al., 2026), yet decision support alerts in general are overridden in most cases (Nanji et al., 2018), so hard rules can generate workarounds.
Central or local? Multihospital systems create formulary subcommittees to handle specialty needs (Treu et al., 2026), raising the question of how far a single formulary can serve diverse units.
10. Measurement problems
There is no standard outcome for formulary quality. Studies count non-formulary approvals (Her et al., 2017), compliance with restrictions (Latifah et al., 2026) or cost savings (Saravdekar et al., 2019). None in the corpus measures whether the knowledge content required by SKS, for example paediatric dose tables, prevents errors.
11. Research gaps and agenda
- Does a formulary with the SKS knowledge content reduce dosing errors in paediatrics and emergencies? (no study found)
- How often are formulary documents consulted, and in what format (printed, intranet, embedded in prescribing software)?
- What share of non-formulary use is clinically justified? (Her et al., 2017)
- Do formulary restrictions enforced through software cause delays or workarounds? (Latifah et al., 2026; Nanji et al., 2018)
- How should pharmacogenomic criteria enter formulary decisions in middle-income settings? (Brown et al., 2025)
12. Implications for practice today
Hospitals can treat the SİY02 formulary as a living, embedded tool rather than a binder: integrate dose tables and interaction information into the prescribing module, review non-formulary use annually (Her et al., 2017), and use information-system checks for restricted drugs while monitoring overrides (Latifah et al., 2026; Nanji et al., 2018).
Summary
- A hospital formulary is both a selection tool and a knowledge tool.
- SKS SİY02 specifies minimum knowledge content, including dose tables and interactions.
- International research focuses on selection, cost and compliance.
- Only five corpus records study the formulary directly; evidence is thin.
- Digital enforcement improves compliance but competes with alert fatigue.
Discussion questions
- Why does SKS emphasise the knowledge content of the formulary?
- Compare a closed formulary with one anchored on a national essential medicines list.
- What risks arise when formulary restrictions are enforced by hard stops?
- Design an audit to check whether the paediatric dose tables in your formulary are used.
- How would you decide whether a non-formulary request is justified?
Further reading
- (Her et al., 2017): a practical model for reviewing non-formulary use.
- (Saravdekar et al., 2019): shows how a national essential medicines list shapes a hospital formulary.
- (Latifah et al., 2026): evaluates compliance with formulary restrictions and digital strategies.
- (Treu et al., 2026): describes specialty subcommittees in a multihospital system.
- (Brown et al., 2025): introduces pharmacogenomics into formulary management.
Glossary
| Turkish | English | Short definition |
|---|---|---|
| Hastane formülerleri | Hospital formulary | Approved list of medicines with prescribing information |
| Formüler dışı ilaç | Non-formulary medication | A drug used without being on the approved list |
| Temel ilaçlar listesi | Essential medicines list | National or WHO list of priority medicines |
| Kısıtlı ilaç | Restricted drug | Drug that may be prescribed only under set conditions |
References
Brown, J. T., Goldwire, M., Massmann, A., Van Heukelom, J., Pasternak, A., Petry, N., Paetznick, C., & Cavallari, L. H. (2025). The impact of pharmacogenomics on a pharmacy and therapeutic committee's formulary system management: An opinion of the pharmacokinetics/pharmacodynamics/pharmacogenomics practice and Research Network for the American College of Clinical Pharmacy. Journal of the American College of Clinical Pharmacy, 8(1), 52-61. https://doi.org/10.1002/jac5.2057
Grabenstein, J. D., Schroeder, D. L., Bjornson, D. C., & Hartzema, A. G. (1992). Pharmacoepidemiology and military medical automation – opportunity for excellence. Military Medicine, 157(6), 302-307. https://doi.org/10.1093/milmed/157.6.302
Her, Q. L., Amato, M. G., Seger, D. L., Gilmore, J. F., Fanikos, J., Fiskio, J. M., & Bates, D. W. (2017). Review of Nonformulary Medication Approvals in an Academic Medical Center. Joint Commission Journal on Quality and Patient Safety, 43(2), 89-96. https://doi.org/10.1016/j.jcjq.2016.10.003
Latifah, E., Pribadi, P., Hidayat, M., Febriliani, S., Yulaikah, A., Putri, A. C. E., Putri, S. S., & Azumah, A. K. (2026). Prescription compliance with National Formulary restrictions: Evaluation and information system-based strategies in an Indonesian tertiary hospital. Pharmacia, 73, Article e183410. https://doi.org/10.3897/pharmacia.73.e183410
Matlala, M., Gous, A. G. S., Godman, B., & Meyer, J. C. (2017). Structure and activities of pharmacy and therapeutics committees among public hospitals in South Africa; findings and implications. Expert Review of Clinical Pharmacology, 10(11), 1273-1280. https://doi.org/10.1080/17512433.2017.1364625
Nanji, K. C., Seger, D. L., Slight, S. P., Amato, M. G., Beeler, P. E., Her, Q. L., Dalleur, O., Eguale, T., Wong, A., Silvers, E. R., Swerdloff, M., Hussain, S. T., Maniam, N., Fiskio, J. M., Dykes, P. C., & Bates, D. W. (2018). Medication-related clinical decision support alert overrides in inpatients. Journal of the American Medical Informatics Association, 25(5), 476-481. https://doi.org/10.1093/jamia/ocx115
Page, R. L., II, Linnebur, S. A., Bryant, L. L., & Ruscin, J. M. (2010). Inappropriate prescribing in the hospitalized elderly patient: Defining the problem, evaluation tools, and possible solutions. Clinical Interventions in Aging, 5, 75-87.
Saravdekar, S., Shukla, V. K., Upadhya, O. P., Rai, M., & Giri, K. (2019). Implementation of principles of pharmacoeconomics and pharmacovigilance to achieve optimal financial and therapeutic benefits through WHO – Essential medicine policy and adoption of NLEM-Based hospital formulary policy. Journal of Family Medicine and Primary Care, 8(6), 1987-1993. https://doi.org/10.4103/jfmpc.jfmpc_287_19
Sağlık Bakanlığı. (2020). Sağlıkta kalite standartları: Hastane (Sürüm 6.1). Sağlık Hizmetleri Genel Müdürlüğü, Sağlıkta Kalite, Akreditasyon ve Çalışan Hakları Dairesi Başkanlığı. https://dosyamerkez.saglik.gov.tr/Eklenti/41258/0/skshastane-seti-s-61–09082021pdf.pdf
Scott, I. A., Pillans, P. I., Barras, M., & Morris, C. (2018). Using EMR-enabled computerized decision support systems to reduce prescribing of potentially inappropriate medications: a narrative review. Therapeutic Advances in Drug Safety, 9(9), 559-573. https://doi.org/10.1177/2042098618784809
Treu, C. N., Vizzi, C., Kum, V., Brown, J., & Farmer, B. (2026). Creation, implementation, and impact of an emergency medicine formulary and therapeutics subcommittee at a large health system. American Journal of Health-System Pharmacy, 83(11), e425-e431. https://doi.org/10.1093/ajhp/zxag047
Source verification and AI use statement
Source verification. All 11 references were generated programmatically from the Web of Science records of the corpus, so authors, year, title, journal and DOI match the records exactly; every in-text citation was cross-checked by code against the reference list. Claims were checked against the record abstracts; full texts were not read. The SKS Hospital Set (Version 6.1) is the only source outside the corpus; it was accessed and read for this chapter.
AI use statement. Claude (Anthropic) was used to merge and de-duplicate the Web of Science exports, assign records to sub-topics, compute the bibliometric indicators and figures, and draft the text under the author’s instructions. The author is responsible for the final content.
Data and supplementary material
Supplementary file S1 (Excel) lists the 95 records of this chapter (authors, year, title, journal, DOI, title match flag), together with the full screening log of the 4948-record corpus and the citation verification report. The list is not reproduced here; it is available from the author on request.
← Chapter 1: Medication Safety GovernanceChapter 3: Rational Drug Use and Antimicrobial Stewardship →